2 10 48 Website A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ). Local URL The URL of the local directory containing all assets of the website <a href="https://lugoneseditorial.com.ar/novedades/diabetes/diabetes-congreso-ada-2024/" target="_blank" rel="noreferrer noopener">https://lugoneseditorial.com.ar/novedades/diabetes/diabetes-congreso-ada-2024/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource La detección y prevención de la diabetes, su diagnóstico y tratamiento, sus complicaciones y comorbilidades asociadas, y el rol de la inteligencia artificial fueron algunos de los temas del Congreso ADA 2024. Entrevista con el Dr. León Litwak, Médico especialista en Endocrinología, Hospital Italiano de Buenos Aires Description An account of the resource Del 21 al 24 de junio de 2024 se celebraron las 84º Sesiones Científicas de la American Diabetes Association (Congreso ADA 2024), en Orlando (Florida), donde se presentaron múltiples novedades referidas a la detección precoz y la prevención, particularmente de la diabetes tipo 1 (DT1), el diagnóstico y tratamiento de las diferentes áreas relacionadas con la DM y la obesidad, las complicaciones y comorbilidades asociadas a la DM y la incorporación gradual de la inteligencia artificial en el campo de la diabetología. Creator An entity primarily responsible for making the resource Cristoforetti, María Fernanda Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 02.08.24 Contributor An entity responsible for making contributions to the resource Litwak, León American Diabetes Association Language A language of the resource Esp complicaciones Congreso ADA 2024León Litwak Diabetes Inteligencia artificial y comorbilidades asociadas https://ciencia.lugoneseditorial.com.ar/files/original/294a8b80a8bccdf3118a4643728e34c6.pdf 7877cc63b77ec708418ed0f4b191410e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/">https://lugoneseditorial.com.ar/novedades/dermatologia/acido-hialuronico-eficacia-seguridad/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Efficacy, safety and satisfaction with the use of Hyaluromax Skin Builder L® Subject The topic of the resource Study confirming the efficacy, safety and satisfaction with the use of hybrid complexes of 1800 kDa hyaluronic acid with 2500 kDa HA Description An account of the resource Study confirming the efficacy, safety and satisfaction with the use of hybrid complexes of 1800 kDa hyaluronic acid with 2500 kDa HA Creator An entity primarily responsible for making the resource Dr. Ana Karina Sanz, Surgeon, MS Medical Center for Advanced Aesthetics, Metropolitan Region, Buin, Chile Source A related resource from which the described resource is derived I. Kim BJ, Choi JH, Lee Y. Development of facial rejuvenation procedures. Thirty years of clinical experience with face lifts. Arch Plast Surg 2015 Sep;42(5):521-31. doi: 10.5999/ aps.2015.42.5.521. II. Alves R, Castro-Esteves T, Trelles MA. Intrinsec and extrinsec factors related to cutaneous aging. Cir Plast Iberol 2013;39(1):89-102. III. Ruiz-Martínez MA, Morales-Hernández MA. Approach to the treatment of skin aging. Ars Pharm 2025;56(4). IV. Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. Dermatol Surg 2008 May;34(5):720-6. doi: 10.1111/j.1524-4725.2008.34176.x. V. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007 Feb;143(2):155-63. doi: 10.1001/ archderm.143.2.155. VI. Goltsova E, Shemonaeva O. Hybrid cooperative complexes of H-HA and L-HA (Profhilo®) and the BAP technique for facial skin bioremodeling: a clinical experience at the NEO-Clinic (Tyumen, Russia). Esperienze Dermatologiche 2019;21:47-53. VII. Trévidic P, Kaufman-Janette J, Weinkle S, Wu R, Dhillon B, Antunes S, Macé E, Maffert P. Injection guidelines for treating midface volume deficiency with hyaluronic acid fillers. The ATP Approach (Anatomy, Techniques, Products). Aesthet Surg J 2022 Aug 1;42(8):920-934. doi: 10.1093/asj/sjac007. VIII. Maytin EV. Hyaluronan: more than just a wrinkle filler. Glycobiology 2016;26(6):553-559. doi: 10.1093/glycob/ cww033. IX. www.futerman.com.ar/hyaluromax. X. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Instrucciones de uso de Hyaluromax Skin Builder L autorizadas por ANMAT. Disponible en:https://helena.anmat.gob.ar/Boletin/. XI. Cassuto D, Bellia G, Schiraldi C. An overview of soft tissue fillers for cosmetic dermatology: from filling to regenerative medicine. Clin Cosmet Investig Dermatol 2021 22;14:1857-1866. doi: 10.2147/CCID.S276676. XII. Enhance Me. Training Academy. Técnica BAP 8. Disponible en: https://www.enhance-me-training.com/ lessons/the-bap-technique/#:~:text=The%20BAP%20 technique%20(bio%20aesthetic%20points)&amp;text=It%20 is%20injected%20in%20the,and%20improvement%20 of%20skin%20turgor. XIII. Vera RV, Morales SMA, Santa CFJ, et al. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Cent Dermatol Pascua 2021;30(2):68- 75. doi:10.35366/101176 Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 11 of december, 2024 Contributor An entity responsible for making contributions to the resource Futerman Language A language of the resource English Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0587">https://doi.org/10.47196/0587</a> 1800 kDa 2500 kDa HA Ana Karina Sanz BAP Technique efficacy Futerman 2 hyaluronic acid Lidocaine Marcelo Robles safety skin aging Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/">https://lugoneseditorial.com.ar/novedades/dermatologia/terapia-oral-psoriasis-deucravacitinib/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Innovative oral therapy for psoriasis Description An account of the resource With high efficacy and a favorable safety profile, deucravacitinib is an innovative oral therapy for moderate to severe plaque psoriasis. Its oral route is a great advantage and promises to significantly improve the management of the disease. Creator An entity primarily responsible for making the resource Dr. Claudio Greco, Dermatologist, Member of the Psoriasis and Vitiligo Group of the Argentine Society of Dermatology, Coordinator of the Hidradenitis Suppurativa Group Source A related resource from which the described resource is derived I. Warren RB, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis. Psoriasis Area and Severity Index (PASI) outcomes over 4 years in patients receiving continuous deucravacitinib in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. II. Warren RB, et al. Deucravacitinib in plaque psoriasis. 4-year efficacy results by prior biologic treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. III. Thaçi D, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease. Response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at the 33rdEuropean Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. IV. Thaçi D, et al. Deucravacitinib efficacy in Psoriasis Area and Severity Index (PASI) target outcomes through 4 years in the phase 3 POETYK trials in moderate to severe plaque psoriasis Presented at the 33rd European Academy of Dermatology & Venereology (EADV) Congress; 25-28 September 2024; Amsterdam, Netherlands. V. Gooderham MJ, Hong CH, Litvinov IV. Selective TYK2 inhibition in the treatment of moderate to severe chronic plaque psoriasis. Skin Therapy Letter 2022;27(6). VI. Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis. A network meta-analysis. Dermatology and Therapy. 2023 Nov;13(11):2839-2857. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editor of Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource December 13th, 2024 Contributor An entity responsible for making contributions to the resource Bristol Language A language of the resource English Bristol Claudio Greco Deucravacitinib efficacy Oral therapy Dengue infection in diabetes Plaque psoriasis Psoriasis Safety profile https://ciencia.lugoneseditorial.com.ar/files/original/4e8e129083aa69bf9ea5e90f0db1110e.pdf 2b1f2a8fe15b39e927ec3e02cfa4038f Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/diabetes/diabetes-rinon/">https://lugoneseditorial.com.ar/diabetes/diabetes-rinon/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Diabetes mellitus y riñón Description An account of the resource “Diabetes mellitus y riñón: enfoque transdisciplinario” es la nueva obra de la Dra. Alicia Elbert. Con la participación de destacados especialistas y el aval de la SAD y la SAN, el libro propone un modelo de atención centrado en el paciente. Disponible en edición impresa y eBook Creator An entity primarily responsible for making the resource Dra. Alicia Elbert Alicia Elbert Diabetes Diabetes mellitus y riñón. Enfoque transdisciplinario Enfermedad renal crónica Enfermedad renal diabética Libro Alicia Elbert Riñón Sociedad Argentina de Diabetes Sociedad Argentina de Nefrología wegovy https://ciencia.lugoneseditorial.com.ar/files/original/738e4f94a76d1997b124c0a0e4747102.pdf d54e247e78243fec40b4b92732e8bbf6 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/diabetes/wegovy-obesidad/">https://lugoneseditorial.com.ar/diabetes/wegovy-obesidad/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Wegovy®: redefiniendo la historia de la obesidad Description An account of the resource Novo Nordisk presentará en Argentina su nuevo tratamiento para la obesidad, Wegovy® (semaglutida 2,4 mg), durante el encuentro virtual “Wegovy®: redefiniendo la historia de la obesidad”, que se realizará el 14 de octubre de 2025 a las 19 h. Creator An entity primarily responsible for making the resource Dra. Mónica Katz, médica especialista en Nutrición, Directora de la Diplomatura en Obesidad de la Universidad Favaloro y referente nacional en obesidad y nutrición clínica. Dra. Almudena Castro Conde, médica cardióloga, Jefa de la Unidad de Rehabilitación Cardíaca del Hospital Universitario La Paz (Madrid, España) y Coordinadora del Grupo de trabajo Diabetes y Obesidad de la Sociedad Española de Cardiología. Source A related resource from which the described resource is derived - Novoenred - Información de producto Wegovy. Certificado N° 59.900 Date A point or period of time associated with an event in the lifecycle of the resource 08/10/2025 obesidad semaglutida wegovy https://ciencia.lugoneseditorial.com.ar/files/original/fae7fc727b7cec893cd1a699fd08f204.pdf 5e9f126e925d57252fa6089324399bad Hyperlink A link, or reference, to another resource on the Internet. Local URL The URL of the local directory containing all assets of the website <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Calcium hydroxyapatite in nasolabial folds Description An account of the resource Evaluation of the safety and efficacy of calcium hydroxyapatite in the treatment of nasolabial folds. Creator An entity primarily responsible for making the resource Editor: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Vera-Ramírez V, Morales-Sánchez MA, Santa-Cruz FJ, Medina-Bojórquez A. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Centro Dermatol Pascua 2021;2:68-75. doi: 10.35366/101176. II. Li K, Meng F, Li YR, Tian Y, Chen H, Jia Q, Cai H, Jiang HB. Application of nonsurgical modalities in improving facial aging. Int J Dent 2022 Feb 24;2022:8332631. doi: 10.1155/2022/8332631. III. Ogden S, Griffiths TW. A review of minimally invasive cosmetic procedures. Br J Dermatol 2008;159:1036-1050. doi: 10.1111/j.1365-2133.2008 .08845.x. IV. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifilogr 2010;101(5):381-393. doi: 10.1016/j.ad.2010.01.004 V. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010 Mar;30(2):235-8. doi: 10.1177/1090820X10366549. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 08/07/2024 Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource Español calcium hydroxyapatite dermal fillers duration efficacy nasolabial folds safety https://ciencia.lugoneseditorial.com.ar/files/original/37a93cbc15677d162bc3db847bc82f81.pdf 5e9f126e925d57252fa6089324399bad Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Hidroxiapatita de calcio en surcos nasolabiales Description An account of the resource Evaluación de la seguridad y eficacia de la hidroxiapatita de calcio en el tratamiento de surcos nasolabiales. Creator An entity primarily responsible for making the resource Editora: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Vera-Ramírez V, Morales-Sánchez MA, Santa-Cruz FJ, Medina-Bojórquez A. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Centro Dermatol Pascua 2021;2:68-75. doi: 10.35366/101176. II. Li K, Meng F, Li YR, Tian Y, Chen H, Jia Q, Cai H, Jiang HB. Application of nonsurgical modalities in improving facial aging. Int J Dent 2022 Feb 24;2022:8332631. doi: 10.1155/2022/8332631. III. Ogden S, Griffiths TW. A review of minimally invasive cosmetic procedures. Br J Dermatol 2008;159:1036-1050. doi: 10.1111/j.1365-2133.2008 .08845.x. IV. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifilogr 2010;101(5):381-393. doi: 10.1016/j. ad.2010.01.004 V. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010 Mar;30(2):235-8. doi: 10.1177/1090820X10366549. Ferreira Pacheco de Oliveira CS, da Silva Almeida TJ, de Oliveira-Martins L, Torelli Marques Sorpreso LA, Silveira Finck N. Hidroxiapatita de cálcio: uma revisão quanto àeficacia, segurança e imaginologia quando usado como preenchedor e como bioestimulador. Research Society and Development 2021;9(14):1-12. doi: 10.33448/ rsd-v10i14.21689. VII. Kadouch J. (2017). Calcium hydroxylapatite. A review on safety and complications. J Cosmet Dermatol 2017;16(2):152-161. doi: 10.1111/jocd.12326. VIII. Berlin A, Cohen JL, Goldberg DJ. Calcium hydroxylapatite for facial rejuvenation. Semin Cutan Med Surg. 2006 Sep;25(3):132-7. doi: 10.1016/j.sder.2006.06.005. IX. Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004 Jul-Aug;6(4):234-9. doi: 10.1001/archfaci.6.4.234. X. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097. XI. Narins RS, Beer K. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg 2006;118(3 Suppl):77S-84S. doi: 10.1097/01. prs.0000234919.25096.67. XII. Ahn MS. Calcium hydroxylapatite: Radiesse. Facial Plast Surg Clin North Am 2007 Feb;15(1):85-90. doi: 10.1016/j. fsc.2006.11.003. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 08/07/2024 Rights Information about rights held in and over the resource Lugones Editorial Format The file format, physical medium, or dimensions of the resource Sitio web Language A language of the resource Español duración eficacia hidroxiapatita de calcio rellenos dérmicos seguridad surcos nasolabiales Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/dermatologia/autoanticuerpos-enfermedades-ampollares/">https://lugoneseditorial.com.ar/dermatologia/autoanticuerpos-enfermedades-ampollares/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Autoanticuerpos en enfermedades ampollares Creator An entity primarily responsible for making the resource Entrevista con el Dr. Julián Reigosa, Bioquímico, Director Técnico, Laboratorio Roquel S.R.L. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 14/04/2026 Contributor An entity responsible for making contributions to the resource Laboratorios Roquel Análisis clínicos Autoanticuerpos Detección autoanticuerpos Detección enfermedades ampollares Enfermedades ampollares Histopatología Inmunofluorescencia directa Laboratorio Roquel Panel de autoanticuerpos Serología Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/desbridamiento-enzimatico/">https://lugoneseditorial.com.ar/novedades/dermatologia/desbridamiento-enzimatico/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Desbridamiento enzimático de heridas Description An account of the resource El desbridamiento enzimático consiste en la eliminación progresiva del tejido desnaturalizado o necrótico de las heridas llevado a cabo por enzimas de aplicación tópica. Creator An entity primarily responsible for making the resource Entrevista con el Dr. Santiago L. Laborde (M. N. 86.746), Médico especialista en Cirugía Plástica y Reconstructiva, Hospital Nacional de Pediatría J. P. Garrahan y Hospital de Quemados (CABA). Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 23 .07.24 Contributor An entity responsible for making contributions to the resource Abbott Language A language of the resource Español Abbott Desbridamiento enzimático Desbridamiento mecánico Desbridamiento quirúrgico Enzima colagenasa Santiago Laborde Tejido desnaturalizado Tejido desvitalizado Tejido necrótico https://ciencia.lugoneseditorial.com.ar/files/original/4a5c3d9e621a089ad33eee26e6893a90.pdf 41e2681074196163f89f9fe9d560d364 Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/dermatologia/desbridamiento-pie-diabetico/">https://lugoneseditorial.com.ar/dermatologia/desbridamiento-pie-diabetico/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Pie diabético: desbridamiento enzimático Description An account of the resource Entrevista con la Dra. Mabel Carrió (M.N. 68739), Médica Diabetóloga, Directora del Centro Municipal de Diabetes Dr. Alberto Maggio y del Hospital de Día de Pie Diabético Malvinas Argentinas, Directora de la Diplomatura de Pie Diabético, Universidad Nacional del Nordeste (UNNE) La colagenasa se emplea para realizar el desbridamiento enzimático en casos de úlceras del pie diabético dado que facilita una transición adecuada entre las distintas fases de cicatrización Creator An entity primarily responsible for making the resource Entrevista con la Dra. Mabel Carrió (M.N. 68739), Médica Diabetóloga, Directora del Centro Municipal de Diabetes Dr. Alberto Maggio y del Hospital de Día de Pie Diabético Malvinas Argentinas, Directora de la Diplomatura de Pie Diabético, Universidad Nacional del Nordeste (UNNE) Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 17/11/2025 Contributor An entity responsible for making contributions to the resource Iruxol - Abbott Abbott Iruxol 3 Beneficios colagenasa Colagenasa Desbridamiento enzimático Fases de cicatrización Mabel Carrió pie diabético Úlceras del pie diabético